Author: | Minsky, B. D. |
Article Title: | Radiation plus chemotherapy as adjuvant therapy for rectal cancer |
Abstract: | The most common neo-adjuvant therapy for rectal cancer is chemotherapy and concurrent radiation therapy. In general, it is delivered pre-operatively for patients with clinical evidence of T3-4 disease or post-operatively in patients who have undergone surgery and have T3 and/or N1-2 disease. This chapter reviews the rationale and results for neo-adjuvant therapy, the selection process for pre-operative versus post-operative treatment, and new approaches and controversies. |
Keywords: | survival; cancer chemotherapy; cancer survival; treatment outcome; survival analysis; cancer surgery; survival rate; clinical trial; review; cancer recurrence; postoperative period; fluorouracil; diarrhea; drug efficacy; multimodality cancer therapy; patient selection; side effect; capecitabine; adjuvant therapy; cancer adjuvant therapy; cancer patient; cancer radiotherapy; postoperative care; preoperative care; radiation dose; chemotherapy, adjuvant; combined modality therapy; neoadjuvant therapy; radiotherapy, adjuvant; cancer staging; antineoplastic agent; evidence based medicine; evidence-based medicine; blood toxicity; antineoplastic combined chemotherapy protocols; risk factors; risk factor; cancer mortality; irinotecan; drug fatality; preoperative period; folinic acid; adjuvant chemotherapy; oxaliplatin; rectal neoplasms; rectum cancer; rectum tumor; hematologic disease; rectum surgery; rectum resection; rectal cancer; anus sphincter; raltitrexed; levamisole; uft; humans; prognosis; human |
Journal Title: | Best Practice & Research: Clinical Gastroenterology |
Volume: | 16 |
Issue: | 2 |
ISSN: | 1521-6918 |
Publisher: | Elsevier Ltd |
Date Published: | 2002-04-01 |
Start Page: | 267 |
End Page: | 282 |
Language: | English |
DOI: | 10.1053/bega.2002.0285 |
PUBMED: | 11969238 |
PROVIDER: | scopus |
DOI/URL: | |
Notes: | Export Date: 14 November 2014 -- Source: Scopus |